Posts

Lumanity’s deep data analytics, value demonstration, and therapeutic area expertise alongside HealthVerity’s patient identity resolution technology and leading ecosystem of interoperable real-world data enables evidence generation across the pharma lifecycle.

The head of the panel of 18 appointees, known as STIKO, said there was no clear case for broad use, citing a lack of data to rule out any rare side effects and no signs of the infection causing severe illness in otherwise healthy children.

GSK is planning a Phase III trial evaluating bepirovirsen as a potential functional cure for chronic hepatitis B infection, despite the most recently released data appearing less robust than the interim analyses. The trial is expected to begin in the first half of 2023.

AbbVie’s investigational neurotoxin, designed to prevent postoperative atrial fibrillation, missed the primary endpoint in a Phase II trial, the company announced Monday.

Vaccine maker Novavax Inc said on Tuesday its COVID-19 shot retooled against the Omicron BA.1 variant showed a strong immune response as the fourth dose and met the main goal of strain change in a late-stage study.

The company announced that its blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market.

Elevalt’s 4Ps proprietary algorithms are the culmination of six years of refining omnichannel execution and are the foundation of the company’s data-driven approach to commercialization.

Through this new partnership, marketers and brands will have off-the-shelf and privacy-optimized access to key consumer groups.

TCR2 Therapeutics announced promising Phase I data for gavo-cel in mesothelin-expression that points toward effects in multiple solid tumors, especially ovarian cancer.

Sam Ingram and Hui Tang reinforce the agency’s commitment to digital experience, and data and analytics.